Skip to main content
Fig. 2 | Cancer Cell International

Fig. 2

From: NY-ESO-1-specific T cell receptor-engineered T cells and Tranilast, a TRPV2 antagonist bivalent treatment enhances the killing of esophageal cancer: a dual-targeted cancer therapeutic route

Fig. 2

Identity characterization of unique TCR clones. a, b dot plots showing the size frequency of each unique αTCR and βTCR, respectively. c, d frequency of all TRAV and TRBV oligonucleotides distributed across each αTCR and βTCR oligonucleotides respective library. e–h, f, frequency distribution of all; αTCR V and J genes (e and f), and βTCR V and J genes (g and h). i the libraries’ frequency distribution of all TCR productive sequences, partial sequences, and frameshifts

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us